Cargando…
Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience
Objective: to describe a single-center experience of Pneumocystis jirovecii pneumonia (PJP) in non-HIV patients recovering from COVID-19. Methods: We report the cases of five non-HIV patients with COVID-19 who also developed PJP at a University Hospital. Results: With the exception of one subject, w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582834/ https://www.ncbi.nlm.nih.gov/pubmed/34769913 http://dx.doi.org/10.3390/ijerph182111399 |
_version_ | 1784597076283228160 |
---|---|
author | Gentile, Ivan Viceconte, Giulio Lanzardo, Amedeo Zotta, Irene Zappulo, Emanuela Pinchera, Biagio Scotto, Riccardo Schiano Moriello, Nicola Foggia, Maria Giaccone, Agnese Messina, Gaetana Salvatore, Paola Buonomo, Antonio Riccardo |
author_facet | Gentile, Ivan Viceconte, Giulio Lanzardo, Amedeo Zotta, Irene Zappulo, Emanuela Pinchera, Biagio Scotto, Riccardo Schiano Moriello, Nicola Foggia, Maria Giaccone, Agnese Messina, Gaetana Salvatore, Paola Buonomo, Antonio Riccardo |
author_sort | Gentile, Ivan |
collection | PubMed |
description | Objective: to describe a single-center experience of Pneumocystis jirovecii pneumonia (PJP) in non-HIV patients recovering from COVID-19. Methods: We report the cases of five non-HIV patients with COVID-19 who also developed PJP at a University Hospital. Results: With the exception of one subject, who experienced an atypical and prolonged course of COVID-19, all the patients developed PJP after the clinical resolution of COVID-19 pneumonia. All but one patient had no pre-existing immunosuppressive conditions or other risk factors for PJP development at COVID-19 diagnosis. Nonetheless, following the course of COVID-19 infection, all the patients fulfilled at least one host factor for PJP; indeed, all the patients had received at least 2 weeks of high-dose steroids and three out of five had a CD4+ cell count <200/mm(3). Conclusions: The use of corticosteroids for COVID-19 respiratory impairment seems to be the most common risk factor for PJP, together with viral-induced and iatrogenic lymphopenia. The worsening in respiratory function and the characteristic radiological picture during or after COVID-19 pneumonia should raise the suspicion of PJP, even in immunocompetent patients. PJP primary chemoprophylaxis can be considered in selected high-risk COVID-19 patients, but further studies are needed. |
format | Online Article Text |
id | pubmed-8582834 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85828342021-11-12 Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience Gentile, Ivan Viceconte, Giulio Lanzardo, Amedeo Zotta, Irene Zappulo, Emanuela Pinchera, Biagio Scotto, Riccardo Schiano Moriello, Nicola Foggia, Maria Giaccone, Agnese Messina, Gaetana Salvatore, Paola Buonomo, Antonio Riccardo Int J Environ Res Public Health Article Objective: to describe a single-center experience of Pneumocystis jirovecii pneumonia (PJP) in non-HIV patients recovering from COVID-19. Methods: We report the cases of five non-HIV patients with COVID-19 who also developed PJP at a University Hospital. Results: With the exception of one subject, who experienced an atypical and prolonged course of COVID-19, all the patients developed PJP after the clinical resolution of COVID-19 pneumonia. All but one patient had no pre-existing immunosuppressive conditions or other risk factors for PJP development at COVID-19 diagnosis. Nonetheless, following the course of COVID-19 infection, all the patients fulfilled at least one host factor for PJP; indeed, all the patients had received at least 2 weeks of high-dose steroids and three out of five had a CD4+ cell count <200/mm(3). Conclusions: The use of corticosteroids for COVID-19 respiratory impairment seems to be the most common risk factor for PJP, together with viral-induced and iatrogenic lymphopenia. The worsening in respiratory function and the characteristic radiological picture during or after COVID-19 pneumonia should raise the suspicion of PJP, even in immunocompetent patients. PJP primary chemoprophylaxis can be considered in selected high-risk COVID-19 patients, but further studies are needed. MDPI 2021-10-29 /pmc/articles/PMC8582834/ /pubmed/34769913 http://dx.doi.org/10.3390/ijerph182111399 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gentile, Ivan Viceconte, Giulio Lanzardo, Amedeo Zotta, Irene Zappulo, Emanuela Pinchera, Biagio Scotto, Riccardo Schiano Moriello, Nicola Foggia, Maria Giaccone, Agnese Messina, Gaetana Salvatore, Paola Buonomo, Antonio Riccardo Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience |
title | Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience |
title_full | Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience |
title_fullStr | Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience |
title_full_unstemmed | Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience |
title_short | Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience |
title_sort | pneumocystis jirovecii pneumonia in non-hiv patients recovering from covid-19: a single-center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582834/ https://www.ncbi.nlm.nih.gov/pubmed/34769913 http://dx.doi.org/10.3390/ijerph182111399 |
work_keys_str_mv | AT gentileivan pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT vicecontegiulio pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT lanzardoamedeo pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT zottairene pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT zappuloemanuela pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT pincherabiagio pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT scottoriccardo pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT schianomoriellonicola pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT foggiamaria pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT giacconeagnese pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT messinagaetana pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT salvatorepaola pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT buonomoantonioriccardo pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience AT pneumocystisjiroveciipneumoniainnonhivpatientsrecoveringfromcovid19asinglecenterexperience |